MASTER trial shows MGuard (InspireMD) offers benefits in treating Coronary Artery Disease

New 6-month results from the MASTER trial demonstrate that the MGuard Embolic Protection Coronary Stent, from InspireMD, outperformed bare metal and drug eluting stents in all-cause mortality in ST segment elevation myocardial infarction (STEMI) patients. The MASTER trial achieved its primary endpoint (p value = 0.008), in complete ST-segment resolution at 60-90 min post-procedure (a strong predictor of mortality).

Secondary endpoint clinical outcomes continue to show a lower mortality rate with MGuard EPS compared to control (0.5% vs. 2.8%, P=0.06) at 6 months. These findings corroborate the previously announced 30-day results showing that all-cause mortality with MGuard EPS was lower than bare metal and drug eluting stents used as a control (0% vs. 1.9%, P=0.06). Results from the trial were presented at the InspireMD STEMI Symposium at EuroPCR.